Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 17/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17228680 | 0.84 | DRD1 (0.57) | DRD1 | |
| SCHEMBL17228776 | 0.82 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17224049 | 0.82 | DRD1 (0.50) | DRD1MAP4K4PDE10A | |
| SCHEMBL17224052 | 0.82 | AXL (0.46) | DRD1MAP4K4 | |
| SCHEMBL17228779 | 0.81 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17224043 | 0.81 | DRD1 (0.58) | DRD1 | |
| SCHEMBL19498239 | 0.70 | HCRTR1 (0.37) | MAP4K4 | |
| SCHEMBL15688121 | 0.69 | DRD1 (0.62) | DRD1 | |
| SCHEMBL17228660 | 0.69 | DRD1 (0.54) | DRD1MAP4K4 | |
| SCHEMBL17228773 | 0.68 | DRD1 (0.50) | DRD1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015166370-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | DRD1 2/4885MAP4K4 1966/4885PDE10A 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.